

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Dullinger Ronald</u> _____ (Last) (First) (Middle) 4505 EMPEROR BLVD SUITE 200 _____ (Street) DURHAM NC 27703 _____ (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 01/01/2026	3. Issuer Name and Ticker or Trading Symbol <u>BIOCRIST PHARMACEUTICALS INC [ BCRX ]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) Chief Commercial Officer	5. If Amendment, Date of Original Filed (Month/Day/Year)  6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Beneficially Owned**

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	258,372 <sup>(1)</sup>	D	

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Emp. Stock Option (Right to Buy)	11/29/2020 <sup>(2)</sup>	11/29/2029	Common Stock	100,000	2.85	D	
Emp. Stock Option (Right to Buy)	12/15/2021 <sup>(3)</sup>	12/15/2030	Common Stock	100,000	8.31	D	
Emp. Stock Option (Right to Buy)	12/14/2022 <sup>(4)</sup>	12/14/2031	Common Stock	41,000	11.43	D	
Emp. Stock Option (Right to Buy)	12/19/2023 <sup>(5)</sup>	12/19/2032	Common Stock	57,100	10.63	D	
Emp. Stock Option (Right to Buy)	12/14/2024 <sup>(6)</sup>	12/14/2033	Common Stock	57,100	6.43	D	
Emp. Stock Option (Right to Buy)	12/19/2025 <sup>(7)</sup>	12/19/2034	Common Stock	68,500	7.39	D	
Emp. Stock Option (Right to Buy)	12/17/2026 <sup>(8)</sup>	12/17/2035	Common Stock	255,050	7.13	D	

**Explanation of Responses:**

- Includes 206,813 restricted stock units which vest 25% on each of the first, second, third and fourth anniversaries of the date of grant.
- Annual Employee Option Grant became exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant. The option was granted on November 29, 2019.
- Annual Employee Option Grant became exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant. The option was granted on December 15, 2020.
- Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant. The option was granted on December 14, 2021.
- Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant. The option was granted on December 19, 2022.
- Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant. The option was granted on December 14, 2023.
- Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant. The option was granted on December 19, 2024.
- Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant. The option was granted on December 17, 2025.

**Remarks:**

Exhibit List: Exhibit 24 - Power of Attorney

/s/ Alane P. Barnes, by

01/09/2026

[power of attorney](#).

\*\* Signature of Reporting  
Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**

## POWER OF ATTORNEY

December 16, 2025

The undersigned hereby constitutes and appoints each of Alane P. Barnes and Sara A. Mykrantz, signing singly and not jointly, with full power of substitution, as the undersigned's true and lawful attorney-in-fact to:

- (1) prepare, execute in the undersigned's name and on the undersigned's behalf, and submit to the U.S. Securities and Exchange Commission (the "SEC") a Form ID, including amendments thereto (the "Form ID"), and any other documents necessary or appropriate to obtain codes and passwords enabling the undersigned to make electronic filings with the SEC of reports required by the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or any rule or regulation of the SEC;
- (2) prepare, execute in the undersigned's name and on the undersigned's behalf, and submit to the SEC, any and all Forms 3, 4, and 5 (the "Section 16 Filings"), including amendments thereto, required to be filed under Section 16(a) of the Exchange Act and the rules thereunder with respect to equity securities of BioCryst Pharmaceuticals, Inc. (the "Company");
- (3) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute such Form ID and any Section 16 Filings (including enrolling the undersigned in EDGAR Next or any successor filing system) and to file such Form ID and any Section 16 Filings with the SEC and any stock exchange or similar authority (including as necessary or desirable to enable the undersigned to act as the undersigned's EDGAR account administrator, manage the undersigned's EDGAR account, and file such Form ID and Section 16 Filings with the SEC via the undersigned's EDGAR account); and
- (4) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming that each such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned hereby authorizes, approves, and ratifies any and all prior actions taken by such attorneys-in-fact in connection with the matters contemplated herein. The undersigned acknowledges that such attorneys-in-fact, in serving in such capacity at the request of the undersigned, do not assume any of the undersigned's responsibilities to comply with the Exchange Act or any rule or regulation of the SEC.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file a Form ID, any Section 16 Filings, or any amendments or changes thereto, with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of the date first written above.

By: /s/ Ronald Dullinger  
Name: Ronald Dullinger